Related Experiment Video
Updated: Aug 26, 2025
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations
1Section of Myelodysplastic Syndromes, Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Abstract:
Single-agent hypomethylating agents remain the cornerstone of treatment for patients with high-risk myelodysplastic syndromes. Although these agents have clinical activity and can improve the overall survival of these patients, their impact on the natural history of myelodysplastic syndromes is only partial. Therefore, we need either newer agents or combinations that could have a greater impact on the survival of our patients. Over the past decade there has been an increased effort in drug development for myelodysplastic syndromes. Hypomethylating agent combinations that have been explored over the past decade include agents that block mutant TP53, NEDD inhibitors, BCL-2 inhibitors, and antibodies such as sabatolimab or magrolimab. Despite initial encouraging results, two registration trials from 2021 and 2022 have not been successful in improving outcomes when compared with single-agent hypomethylating agents. Here, I summarise the current status of ongoing phase 3 trials for patients with untreated high-risk myelodysplastic syndromes and provide some suggestions for future designs.
Insights
High-risk myelodysplastic syndromes treatments using hypomethylating agents show partial survival benefits. Newer combinations are needed to improve patient outcomes, as recent trials have not surpassed current standards of care.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Single-agent hypomethylating agents are standard for high-risk myelodysplastic syndromes.
- These treatments offer partial survival improvement but do not alter the disease's natural history substantially.
- There is a critical need for novel therapeutic strategies to enhance patient survival.
Purpose of the Study:
- To review the current landscape of Phase 3 clinical trials for untreated high-risk myelodysplastic syndromes.
- To discuss the status of ongoing investigations into novel combination therapies.
- To propose future clinical trial designs for improved treatment efficacy.
Main Methods:
- Review of recent clinical trial data for myelodysplastic syndromes.
- Analysis of combination therapies including TP53 inhibitors, NEDD inhibitors, BCL-2 inhibitors, and monoclonal antibodies.
- Summary of ongoing Phase 3 trial outcomes and future directions.
Main Results:
- Despite extensive research, recent registration trials (2021-2022) combining hypomethylating agents with novel agents failed to demonstrate superior outcomes compared to single-agent hypomethylating agents.
- Various combination strategies have been explored, including those targeting mutant TP53, NEDDylation, BCL-2, and immune checkpoints with antibodies like sabatolimab and magrolimab.
Conclusions:
- Current combination therapies have not yet surpassed the efficacy of single-agent hypomethylating agents for high-risk myelodysplastic syndromes.
- Further research and innovative clinical trial designs are essential to develop more impactful treatments.
- Future strategies may involve different combinations or patient stratification to improve survival in myelodysplastic syndromes.
More Related Videos
12:05Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview